PDF herunterladen
Diabetologie und Stoffwechsel 2019; 14(02): 109-123
DOI: 10.1055/s-0044-101862
CME-Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Labordiagnostik bei Diabetes mellitus

Laboratory management of diabetes mellitus
Sebastian Hörber
,
Erwin Schleicher
,
Andreas Peter
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. April 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Laboratory parameters are essential for diagnosis, prognosis and therapy control of diabetes mellitus. Diabetes-specific parameters including glucose, glycated hemoglobin (HbA1c), C-peptide and autoantibodies against beta cell epitopes as well as parameters of lipid metabolism and renal function should be taken into account. The precise and reliable determination of these parameters in accordance with the guidelines of the German Federal Medical Council for the determination of laboratory diagnostics is fundamental for the correct classification and evaluation of the measurement results. For this, important pre-analytical and analytical limitations must be considered.

Laborparameter spielen eine zentrale Rolle in der Diagnose, Prognose und Therapiekontrolle des Diabetes mellitus. Dabei sollten auch Parameter des Lipidstoffwechsels und der Nierenfunktion berücksichtigt werden. Die genaue und zuverlässige Bestimmung der Parameter ist für die Einordnung der Messergebnisse entscheidend. Dabei sind die Vorgaben der „Rili-BÄK“ einzuhalten sowie wichtige präanalytische und analytische Limitationen zu beachten.

Schlüsselwörter

Labordiagnostik - Diabetes mellitus - Präanalytik - Messmethoden - Grenzwerte

Key words

laboratory diagnostics - diabetes mellitus - pre-analytics - measurement methods - thresholds
 

  • Literatur

  • 1 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41: S13-S27 . doi:10.2337/dc18-S002
    CrossrefPubMedGoogle Scholar
  • 2 Bundesärztekammer. Richtlinie zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Dtsch Arztebl 2008; 105: A341-A355
    Google Scholar
  • 3 Deutsche Diabetes Gesellschaft. Stellungnahme der Kommission Labordiagnostik in der Diabetologie (KLD) zum Wert und Sinn der Minimal Difference (MD) als Beurteilungskriterium für die laboranalytische Messqualität. 2017 Im Internet: http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Stellungnahmen/2017/DDG_Stellungnahme_MD.pdf ; Stand: 20.03.2019
    PubMedGoogle Scholar
  • 4 Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805 . doi:10.1136/bmj.d3805
    CrossrefPubMedGoogle Scholar
  • 5 Choudhary P, Ramasamy S, Green L. et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care 2013; 36: 4160-4162 . doi:10.2337/dc13-0939
    CrossrefPubMedGoogle Scholar
  • 6 Nauck M, Petersmann A, Müller-Wieland D. et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2017; 12 (Suppl. 02) S94-S100
    Artikel in Thieme ConnectGoogle Scholar
  • 7 Gambino R, Piscitelli J, Ackattupathil TA. et al. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis. Clin Chem 2009; 55: 1019-1021 . doi:10.1373/clinchem.2008.121707
    CrossrefPubMedGoogle Scholar
  • 8 Gambino R. Sodium fluoride: an ineffective inhibitor of glycolysis. Ann Clin Biochem 2013; 50: 3-5 . doi:10.1258/acb.2012.012135
    CrossrefPubMedGoogle Scholar
  • 9 Sacks DB, Arnold M, Bakris GL. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011; 57: e1-e47 . doi:10.1373/clinchem.2010.161596
    CrossrefPubMedGoogle Scholar
  • 10 Winter T, Hannemann A, Suchsland J. et al. Long-term stability of glucose: glycolysis inhibitor vs. gel barrier tubes. Clin Chem Lab Med 2018; 56: 1251-1258 . doi:10.1515/cclm-2017-0860
    CrossrefPubMedGoogle Scholar
  • 11 Petersmann A, Nauck M, Muller-Wieland D. et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes 2018; 126: 406-410 . doi:10.1055/a-0584-6223
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Kleinwechter H. Update gestational diabetes – the new guidelines. MMW Fortschr Med 2011; 153: 44-47
    PubMedGoogle Scholar
  • 13 Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239-2244 . doi:10.1007/s00125-007-0803-0
    CrossrefPubMedGoogle Scholar
  • 14 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefPubMedGoogle Scholar
  • 15 EurA1c Trial Group. EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. Clin Chem 2018; 64: 1183-1192 . doi:10.1373/clinchem.2018.288795
    CrossrefPubMedGoogle Scholar
  • 16 Kaiser P, Spannagl M, van Campenhout C. et al. HbA1c: EQA in Germany, Belgium and the Netherlands using fresh whole blood samples with target values assigned with the IFCC reference system. Clin Chem Lab Med 2016; 54: 1769-1775 . doi:10.1515/cclm-2016-0123
    PubMedGoogle Scholar
  • 17 Dagogo-Jack S. Pitfalls in the use of HbA(1)(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589-593 . doi:10.1038/nrendo.2010.126
    CrossrefPubMedGoogle Scholar
  • 18 Peter A, Fritsche A, Stefan N. et al. Diagnostic value of hemoglobin A1c for type 2 diabetes mellitus in a population at risk. Exp Clin Endocrinol Diabetes 2011; 119: 234-237 . doi:10.1055/s-0030-1270440
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 19 Selvin E, Warren B, He X. et al. Establishment of community-based reference intervals for fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clin Chem 2018; 64: 843-850 . doi:10.1373/clinchem.2017.285742
    CrossrefPubMedGoogle Scholar
  • 20 Selvin E, Rawlings AM, Grams M. et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol 2014; 2: 279-288 . doi:10.1016/S2213-8587(13)70199-2
    CrossrefPubMedGoogle Scholar
  • 21 Kohzuma T, Yamamoto T, Uematsu Y. et al. Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 2011; 5: 1455-1462 . doi:10.1177/193229681100500619
    CrossrefPubMedGoogle Scholar
  • 22 Koga M, Matsumoto S, Saito H. et al. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 2006; 53: 387-391
    CrossrefPubMedGoogle Scholar
  • 23 Kishimoto M, Yamasaki Y, Kubota M. et al. 1,5-anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995; 18: 1156-1159
    CrossrefPubMedGoogle Scholar
  • 24 Kim MJ, Jung HS, Hwang-Bo Y. et al. Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol 2013; 50: 505-510 . doi:10.1007/s00592-011-0302-0
    CrossrefPubMedGoogle Scholar
  • 25 Balis DA, Tong C, Meininger G. Effect of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol. J Diabetes 2014; 6: 378-380 . doi:10.1111/1753-0407.12116
    CrossrefPubMedGoogle Scholar
  • 26 Staten MA, Stern MP, Miller WG. et al. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010; 33: 205-206 . doi:10.2337/dc09-1206
    CrossrefPubMedGoogle Scholar
  • 27 Little RR, Wielgosz RI, Josephs R. et al. Implementing a reference measurement system for C-peptide: successes and lessons learned. Clin Chem 2017; 63: 1447-1456 . doi:10.1373/clinchem.2016.269274
    CrossrefPubMedGoogle Scholar
  • 28 Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010; 95: 25-33 . doi:10.1210/jc.2009-1365
    CrossrefPubMedGoogle Scholar
  • 29 Achenbach P, Schlosser M, Williams AJ. et al. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 2007; 122: 85-90 . doi:10.1016/j.clim.2006.09.004
    CrossrefPubMedGoogle Scholar
  • 30 Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34: 1878-1884 . doi:10.2337/dc11-0035
    CrossrefPubMedGoogle Scholar
  • 31 Merker L, Ebert T, Guthoff M. et al. Nephropathie bei Diabetes. Diabetologie 2018; 13 (Suppl. 02) S217-S221 . doi:10.1055/a-0598-0566
    Artikel in Thieme ConnectGoogle Scholar
  • 32 Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058 . doi:10.1093/eurheartj/ehw272
    CrossrefPubMedGoogle Scholar
  • 33 Nordestgaard BG, Langsted A, Mora S. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cutpoints – a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2016; 62: 930-946 . doi:10.1373/clinchem.2016.258897
    CrossrefPubMedGoogle Scholar
  • 34 Nordestgaard BG, Langsted A, Mora S. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points – a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958 . doi:10.1093/eurheartj/ehw152
    CrossrefPubMedGoogle Scholar
  • 35 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
    CrossrefPubMedGoogle Scholar
  • 36 Levey AS, Coresh J, Greene T. et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772 . doi:10.1373/clinchem.2006.077180
    CrossrefPubMedGoogle Scholar
  • 37 Larsson A, Malm J, Grubb A. et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004; 64: 25-30
    CrossrefPubMedGoogle Scholar
  • 38 Diabetes, Control Complications Trial Research. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; DOI: 10.1056/NEJM199309303291401.
    CrossrefPubMedGoogle Scholar
  • 39 Hörber S, Achenbach P, Schleicher E. et al. Harmonization of immunoassays for biomarkers in diabetes mellitus. Biotechnol Adv 2019 Feb 23. pii: S0734-9750(19)30034-5. DOI: 10.1016/j.biotechadv.2019.02.015 [Epub ahead of print]
    CrossrefPubMedGoogle Scholar